TOP 5 MOST VIEWED ARTICLES

RECENT COMMENTS

Azmina: In my personal experience, Medical Oncology teams would love to be able to offer patients concurrent [...]   »Read more

Storme Guy: I agree that false promises or prediction are done in a non correct way. Always, medical oncologist [...]   »Read more

Alex: You use EUS for staging only the smaller tumours. What about using endoscopic mucosal resection for [...]   »Read more

dinha: Please write your comment here   »Read more

headcoverings for chemotherapy: I recently came across your blog and have been reading along. I thought I would leave my first c [...]   »Read more

 

Article type: Impact Factor

Keywords: rhabdomyosarcoma, childhood cancer, .

This article has 1 comments

Facebook Twitter Share - Send - Print - Pdf

 

Minimising radiotherapy in children with rhabdomyosarcoma

US and European paediatric oncologists are finally finding common ground over which patients need potentially damaging aggressive local treatment, and which can be spared.

» Alex Mathieson


To read the complete article please click on the pdf icon
 
COMMENTS (1)
 
Kelly Dickson (Rhabdomyosarcoma) says: 07 June 2010 07:02:10
My good friend's son has Rhabdomyosarcoma in his jaw. He was diagnosed nearly 6 years ago at the age of 6. He had chemo and radiation. It then reappeared at the age of 9. He went through an operation and now has a stint in his face to hold it up. He once again underwent treatment. He is now 11yrs and it has come back. The doctors told the parents that there is not a lot more that can be done. He is undergoing radiation every day this week to try and shrink the tumour. I know we have good hospitals in Australia however I do not count out the possibility that other countries also have great treatments that we may not have. I would like to know if there is anything else out there that could help Riley.
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, Celgene, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck Serono, Novartis, Roche and Sanofi Aventis.